Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.88 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227355 | 0.94 | GSK3B (1.00) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| SCHEMBL689331 | 0.89 | GSK3B (0.83) | GSK3BPTPN1RAB9AALDH1A1LMNA | |
| Methylsulfanylmethane SCHEMBL28782225 | 0.88 | GSK3B (0.88) | GSK3BPTPN1NPC1RAB9AKMT2A | |
| SCHEMBL18209648 | 0.83 | GSK3B (0.68) | GSK3BPTPN1KMT2AMMP2MMP9 | |
| SCHEMBL205280 | 0.82 | GSK3B (0.80) | GSK3BPTPN1NPC1RAB9A | |
| SCHEMBL5308744 | 0.81 | GSK3B (0.59) | GSK3BPTPN1ALDH1A1CES2CES1 | |
| SCHEMBL316871 | 0.81 | GSK3B (1.00) | GSK3BPTPN1RAB9AALDH1A1LMNA | |
| SCHEMBL22004470 | 0.81 | GSK3B (1.00) | GSK3BPTPN1RAB9AALDH1A1LMNA | |
| SCHEMBL2633141 | 0.81 | SMN1; SMN2 (0.70) | GSK3BNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL973263 | 0.81 | GSK3B (0.87) | GSK3BPTPN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9700543-B2 | GLP-1 receptor stabilizers and modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-07-11 | — | — | US | disclosed |
| EP-2713722-B1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160310471-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2016-10-27 | — | — | US | disclosed |
| US-9278910-B2 | GLP-1 receptor stabilizers and modulators | RECEPTOS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140336185-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS LLC | 2014-11-13 | — | — | US | disclosed |
| WO-2012166951-A9 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012166951-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | RECEPTOS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| EP-1031349-A1 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases | Bayer Aktiengesellschaft (DE) | 2000-08-30 | — | — | EP | disclosed |
| US-4536517-A | ANTIDIABETIC, ANTILIPEMIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336185-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | GLP1R, GIPR, GHSR | GSK3B 1614/4885PTPN1 426/4885NPC1 3413/4885 |
| US-20160310471-A1 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS | GLP1R, GIPR, GHSR | GSK3B 1614/4885PTPN1 426/4885NPC1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.